TOI — Starling Oncology, Inc.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1799191 ·
Last close
$6.20
Market Cap
$619.89M
52W High
$7.05
52W Low
$4.85
ADV30
2,242,555
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 161,282,000 | 27,165,000 | -4,616,000 | -9,789,000 | 178,233,000 | 41,094,000 | 203,147,000 |
| Mar 2026 | 147,441,000 | 23,315,000 | -6,513,000 | -2,492,000 | 168,230,000 | 30,280,000 | 184,515,000 |
| Dec 2025 | 141,957,000 | 22,765,000 | -6,907,000 | -7,508,000 | 164,656,000 | 33,565,000 | 180,376,000 |
| Sep 2025 | 136,564,000 | 18,920,000 | -8,054,000 | -16,504,000 | 163,619,000 | 27,658,000 | 175,893,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$328,000
Investing CF
$-3,614,000
Financing CF
$14,088,000
CapEx
$-3,614,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.30
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-283,700,000
Inventory
$20,011,000
Receivables
$66,709,000
ST Investments
$0
EBIT TTM
$-28,664,000
Pretax Income TTM
$-36,293,000
Interest Exp TTM
$7,629,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$545,763,968
EBITDA
$-25,909,000
Free Cash Flow
$-15,312,625
Enterprise Value
$587,545,472
Total Cash
$30,280,000
Total Debt
$104,913,000
Shares Out
99,982,933
Trailing EPS
$-0.35
Book Value
$-0.16
ROE
—
ROA
-12.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 502,729,000 | -36,083,000 | -60,606,000 | 164,656,000 | 180,376,000 | — | -24,587,000 |
| Dec 2024 | 393,412,000 | -60,118,000 | -64,663,000 | 172,717,000 | 169,128,000 | — | -26,538,000 |
| Dec 2023 | 324,239,000 | -60,151,000 | -83,068,000 | 209,240,000 | 152,215,000 | — | -36,315,000 |
| Dec 2022 | 252,483,000 | -72,007,000 | 152,000 | 261,665,000 | 138,490,000 | — | -61,756,000 |
TTM Snapshot
Revenues TTM
$363,872,000
NetIncome TTM
$-67,064,000
OpCashFlow TTM
$0
Assets (Latest)
$172,717,000
Forward EPS
$-0.16
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FLGT | Fulgent Genetics, Inc. | $535.17M | $19.45 | — |
| SRTA | Strata Critical Medical, Inc. | $528.15M | $5.97 | — |
| AHCO | AdaptHealth Corp. | $765.98M | $5.63 | — |
| MCTA | Charming Medical Ltd | $445.55M | $29.35 | — |
| TALK | Talkspace, Inc. | $870.58M | $5.25 | — |
News headlines (Yahoo Finance, 1h cache)
The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call
2026-07-27 13:00 · Yahoo
Is Oncology Institute (TOI) One of the Best Future Stocks to Buy Under $10?
2026-07-16 19:39 · Yahoo
Why Oncology Institute’s (TOI) Analyst Upgrades Put Its Community Cancer Care Growth Story in Focus
2026-07-07 07:43 · Yahoo
The Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock?
2026-06-29 14:30 · Yahoo
The Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring Conference
2026-05-26 13:00 · Yahoo
The Oncology Institute, Inc. (NASDAQ:TOI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$7.00
2026-05-11 16:06 · Yahoo
Oncology Institute Q1 Earnings Call Highlights
2026-05-09 05:06 · Yahoo
The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 23:05 · Yahoo
The Oncology Institute Rebrands as Starling Oncology
2026-08-03 12:00 · Yahoo
The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
2026-07-07 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.